PCRX Stock Analysis: Pacira BioSciences | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.004m USD | 12M Return: 9.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.3M
EPS Trend: -34.9%
Qual. Beats: 0
Rev. Trend: 98.8%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pacira BioSciences is a U.S.-based specialty pharmaceutical company focused on non-opioid pain management and regenerative health solutions for healthcare practitioners. Its commercial portfolio centers on EXPAREL, a long-acting local anesthetic for postsurgical pain; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain; and the iovera cryoanalgesia system, which uses controlled cold to block peripheral nerve pain signals.
The company is also advancing PCRX-201, an intra-articular gene therapy candidate for osteoarthritis, and maintains a veterinary partnership with Aratana Therapeutics for NOCITA, a bupivacaine liposome injectable for animal use. The business model combines proprietary drug delivery platforms (notably multivesicular liposome technology used in EXPAREL) with device-based interventions, positioning Pacira within the broader effort to reduce reliance on opioid-based pain therapies in both human and animal health markets.
Originally incorporated in 2006 as Pacira Pharmaceuticals, the company rebranded as Pacira BioSciences in April 2019, reflecting its strategic expansion from specialty injectables into regenerative medicine and gene therapy. It is headquartered in Brisbane, California, and trades on NASDAQ under the ticker PCRX.
- EXPAREL postsurgical sales volume drives quarterly revenue growth
- ZILRETTA faces pricing pressure from generic steroids and reimbursement cuts
- PCRX-201 gene therapy pipeline advances for osteoarthritis treatment
| Net Income: 5.14m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 0.93 > 1.0 |
| NWC/Revenue: 55.27% < 20% (prev 63.35%; Δ -8.08% < -1%) |
| CFO/TA 0.12 > 3% & CFO 142.2m > Net Income 5.14m |
| Net Debt (252.5m) to EBITDA (118.4m): 2.13 < 3 |
| Current Ratio: 4.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.9m) vs 12m ago -12.07% < -2% |
| Gross Margin: 79.34% > 18% (prev 77.61%; Δ 1.72% > 0.5%) |
| Asset Turnover: 52.58% > 50% (prev 44.29%; Δ 8.29% > 0%) |
| Interest Coverage Ratio: 1.83 > 6 (EBIT TTM 27.2m / Interest Expense TTM 14.9m) |
| A: 0.34 (Total Current Assets 515.0m - Total Current Liabilities 108.8m) / Total Assets 1.21b |
| B: -0.16 (Retained Earnings -196.4m / Total Assets 1.21b) |
| C: 0.02 (EBIT TTM 27.2m / Avg Total Assets 1.40b) |
| D: 1.18 (Book Value of Equity 653.9m / Total Liabilities 554.6m) |
| Altman-Z'' = 3.04 = A |
| DSRI: 1.15 (Receivables 125.6m/104.7m, Revenue 734.9m/702.8m) |
| GMI: 0.98 (GM 77.61% / 79.34%) |
| AQI: 1.11 (AQ_t 0.43 / AQ_t-1 0.39) |
| SGI: 1.05 (Revenue 734.9m / 702.8m) |
| TATA: -0.11 (NI 5.14m - CFO 142.2m) / TA 1.21b) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at USD 25.54 with a total of 437,576 shares traded. Over the past week, the price has changed by -0.20%, over one month by +12.31%, over three months by +6.15% and over the past year by +9.57%.
Current recommended Stop Loss: 23.10 (which is 9.6% or 2.7 ATR below the current price).
Pacira BioSciences has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy PCRX.
- StrongBuy: 3
- Buy: 1
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 29.7 | 16.2% |
P/E Trailing = 196.3077
P/E Forward = 8.6655
P/S = 1.3825
P/B = 1.5284
P/EG = 11.2121
Revenue TTM = 734.9m USD
EBIT TTM = 27.2m USD
EBITDA TTM = 118.4m USD
Long Term Debt = 367.7m USD (from longTermDebt, last quarter)
Short Term Debt = 9.82m USD (from shortTermDebt, last quarter)
Debt = 454.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 43.5m
Net Debt = 252.5m USD (calculated: Debt 454.7m - CCE 202.2m)
Enterprise Value = 1.26b USD (1.00b + Debt 454.7m - CCE 202.2m)
Interest Coverage Ratio = 1.83 (Ebit TTM 27.2m / Interest Expense TTM 14.9m)
EV/FCF = 9.47x (Enterprise Value 1.26b / FCF TTM 132.7m)
FCF Yield = 10.56% (FCF TTM 132.7m / Enterprise Value 1.26b)
FCF Margin = 18.06% (FCF TTM 132.7m / Revenue TTM 734.9m)
Net Margin = 0.70% (Net Income TTM 5.14m / Revenue TTM 734.9m)
Gross Margin = 79.34% ((Revenue TTM 734.9m - Cost of Revenue TTM 151.9m) / Revenue TTM)
Gross Margin QoQ = 79.47% (prev 79.53%)
Tobins Q-Ratio = 1.04 (Enterprise Value 1.26b / Total Assets 1.21b)
Interest Expense / Debt = 3.28% (Interest Expense 14.9m / Debt 454.7m)
Taxrate = 41.66% (2.08m / 5.00m)
NOPAT = 15.9m (EBIT 27.2m * (1 - 41.66%))
Current Ratio = 4.73 (Total Current Assets 515.0m / Total Current Liabilities 108.8m)
Debt / Equity = 0.70 (Debt 454.7m / totalStockholderEquity, last quarter 653.9m)
Debt / EBITDA = 2.13 (Net Debt 252.5m / EBITDA 118.4m)
Debt / FCF = 1.90 (Net Debt 252.5m / FCF TTM 132.7m)
Total Stockholder Equity = 708.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.37% (Net Income 5.14m / Total Assets 1.21b)
RoE = 0.73% (Net Income TTM 5.14m / Total Stockholder Equity 708.0m)
RoCE = 2.53% (EBIT 27.2m / Capital Employed (Equity 708.0m + L.T.Debt 367.7m))
RoIC = 1.48% (NOPAT 15.9m / Invested Capital 1.07b)
WACC = 3.68% (E(1.00b)/V(1.46b) * Re(4.48%) + D(454.7m)/V(1.46b) * Rd(3.28%) * (1-Tc(0.42)))
Discount Rate = 4.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.62 | Cagr: -10.16%
[DCF] Terminal Value 73.10% ; FCFF base≈143.4m ; Y1≈125.7m ; Y5≈101.6m
[DCF] Fair Price = 35.02 (EV 1.63b - Net Debt 252.5m = Equity 1.38b / Shares 39.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -34.89 | EPS CAGR: -4.04% | SUE: 0.29 | # QB: 0
Revenue Correlation: 98.82 | Revenue CAGR: 3.52% | SUE: 1.03 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.65 | Chg30d=+2.36% | Revisions=-50% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.76 | Chg30d=+1.29% | Revisions=+44% | Analysts=6
EPS current Year (2026-12-31): EPS=2.88 | Chg30d=+0.68% | Revisions=+50% | GrowthEPS=+8.6% | GrowthRev=+5.7%
EPS next Year (2027-12-31): EPS=3.65 | Chg30d=+0.93% | Revisions=+50% | GrowthEPS=+26.8% | GrowthRev=+8.3%
[Analyst] Revisions Ratio: +30% (up=18, down=9)